Stockreport

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company [Read more]